Advanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges

Yolanda Diebold; Laura García-Posadas

doi:10.3390/pharmaceutics13111819

Advanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges

Pharmaceutics. 2021 Nov 1;13(11):1819. doi: 10.3390/pharmaceutics13111819.

Authors

Yolanda Diebold^{1

2}, Laura García-Posadas¹

Affiliations

¹ Ocular Surface Group, Instituto de Oftalmobiología Aplicada (IOBA), Universidad de Valladolid, 47011 Valladolid, Spain.
² Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.

PMID: 34834234
PMCID: PMC8621516
DOI: 10.3390/pharmaceutics13111819

Abstract

Advanced therapy medicinal products (ATMPs) are a novel class of medicines with enormous potential to improve treatments for a wide range of diseases, including those affecting eye structures [...].

Publication types

Editorial

Grants and funding

RTI2018-094071-B-C2/Ministerio de Ciencia, Innovación y Universidades (MCIU, Government of Spain), Agencia Esta-tal de Investigación (AEI, Government of Spain), and the Fondo Europeo de Desarrollo Regional (FEDER)
Postdoctoral contracts 2017 call/University of Valladolid